Therefore, it is evident that LPA1 and LPA3 signal inhibitors, including receptors antagonist and inhibitors of enzymes for LPA synthesis would be promising to successfully treat the CPSP, as reported in the case of experimental fibromyalgia-like pain models (Ueda and Neyama, 2017). The gene discussed is LPAR3; the disease is fibromyalgia.